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Abstract
New chemistry methods for the synthesis of radiolabeled small molecules have the potential to impact clinical positron
emission tomography (PET) imaging, if they can be successfully translated. However, progression of modern reactions from
the stage of synthetic chemistry development to the preparation of radiotracer doses ready for use in human PET imaging is
challenging and rare. Here we describe the process of and the successful translation of a modern palladium-mediated
fluorination reaction to non-human primate (NHP) baboon PET imaging–an important milestone on the path to human PET
imaging. The method, which transforms [
18F]fluoride into an electrophilic fluorination reagent, provides access to aryl–
18F
bonds that would be challenging to synthesize via conventional radiochemistry methods.
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Introduction
Positron emission tomography (PET) is a non-invasive imaging
technique used to characterize and diagnose disease [1,2].
Historically, PET imaging has been limited by chemistry. There
are few convenient and efficient methods to incorporate positron-
emitting isotopes into small molecules of imaging interest. Several
positron-emitting isotopes are used for PET imaging, including
carbon-11, nitrogen-13, oxygen-15, and copper-64, but due to its
suitable half-life for synthesis and imaging, fluorine-18 (
18F) is the
most common and most relevant isotope for clinical PET [3,4].
Additionally, fluorine is present in a variety of biologically active
molecules and pharmaceuticals [5,6]. However, synthesis with
18F
is difficult due to time restrictions (half-life of
18F: 110 min) and
mass restrictions (scale of synthesis: nanomoles), among others [7].
Thus the general chemical challenges associated with carbon–
fluorine bond formation [8,9,10] are exacerbated for
18F-
radiotracer synthesis. Modern methods for the construction of
carbon–fluorine bonds are changing the landscape of molecules
considered viable for PET [9]. The new chemical methods hold
the unrealized potential of changing radiotracer design and
development. A critical, non-trivial step is the development of
modern fluorination methods from the stage of synthetic chemistry
to the preparation of radiotracer doses ready for in vivo PET
imaging. Here we describe the first successful development of a
modern palladium-mediated fluorination reaction to be used for
non-human primate (NHP) PET imaging–an important milestone
on the path to human PET imaging.
The imaging candidates reported here were chosen for
structural motifs that are representative of drug-like small
molecules, and were intended to highlight the utility of
transition-metal-mediated carbon–fluorine bond formation to
overcome chemical challenges associated with
18F chemistry.
The challenges include: 1)
18F radiochemistry requires fast
reaction rates because the concentration of the limiting reagent
(fluoride) is small (mM) compared to typical synthetic reactions
(mM to M). Slow reaction rates are often overcome by elevating
reaction temperatures, which can lead to side reactions and
product decomposition, especially for complex small molecules. 2)
18F is available in nucleophilic and electrophilic forms, but only
the nucleophilic form, [
18F]fluoride, is readily available and can be
made in high specific activity [7,11]. Specific activity is a
measurement of the amount of radioactivity per molar amount
of sample. High specific activity, though not necessary for all PET
applications, is important for imaging biological targets of low
concentration, like imaging of neurotransmitter receptors in the
brain [4]. For pharmacokinetic measurements, specific activity is
less critical. 3) [
18F]Fluoride is created by the proton bombard-
ment of [
18O]H2O. While removal of the bulk water is common
for synthesis with
18F, the large hydration energy [12,13,14] and
the small amount of fluoride prevents rigorous drying. Hydrated
fluoride is less nucleophilic than dry fluoride and therefore cannot
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e59187be used in many nucleophilic fluorination reactions. Most recently
developed fluorination reactions do not meet or have yet to meet
one or more of the above considerations. For example, reactions
that require dry solvent or long reaction times are difficult to
transition to radiochemistry, even if yields are high for the
fluorination reactions with
19F, the natural isotopologue.
Once chemistry with
18F is feasible (i.e. a fluorination reaction
can be accomplished with
18F, and a radiochemical yield (RCY)
can be determined), the reaction still may not lead to a practical
synthesis method for molecules useful for PET imaging experi-
ments [15]. Most importantly, radiochemistry techniques must
allow for efficient purification due to time constraints. The
formation of constitutional isomers that are difficult-to-separate
must be minimized during synthesis, and starting materials as well
as byproducts must be removable from the desired sample. In
particular hydro-defluoro and halo-defluoro (halo=chloro, bro-
mo, iodo) can be difficult to separate from radiofluorinated
material. Final samples must be radiochemically and chemically
pure and sterile. Additionally, a substantial quantity of radioac-
tivity must be obtained at the end of synthesis; typically 5–10 mCi
per experiment for non-human primates is suitable for imaging
[1]. Automated robotic procedures are utilized to handle this
amount of radioactivity.
Two molecules, targeting the serotonin neurotransmitter
system, were identified and selected for transitioning our new
fluorination method to PET imaging applications [16]. Each
molecule represents one example of the two general functional
uses of PET imaging in drug discovery: 1) labeling a drug to assess
its biodistribution as well as pharmacokinetic and metabolic
profile; and 2) labeling a bioactive molecule to evaluate its
potential as a radiotracer, a marker of a biological system [17]. For
the labeled drug example, paroxetine (1), an antidepressant
selective serotonin reuptake inhibitor (SSRI) medication with
nearly 13 million prescriptions in the US in 2010 [18], was
selected (Figure 1). Despite its widespread use, the pharmacoki-
netic profile and distribution of paroxetine binding in the human
brain are unknown. There has been previous interest in labeling
paroxetine for PET imaging in humans [19], but only paroxetine
derivatives [20], not paroxetine itself, could be labeled with
18F,
presumably due to lack of appropriate chemistry methods. As a
representative molecule for the second class, the 5-HT2C agonist 2
[21] was selected for evaluation as a potential radiotracer for
imaging 5-HT2C receptors, an important target in the develop-
ment of new drugs to treat obesity [22] and a target for which no
radiotracer exists (5-HT=5-hydroxytryptamine=serotonin) [23].
Both molecules would be difficult to radiolabel with
18F using
conventional fluorination strategies.
We recently reported a conceptually different arene radio-
fluorination reaction that relies on C–F bond formation at a
transition metal center [24]. The novelty of the method consists of
[
18F]fluoride capture to form an electrophilic fluorination reagent
that could be used for late-stage fluorination. The development
and translation of the method into a reliable, reproducible arene
radiofluorination method that can afford radiolabeled molecules
on a scale suitable for PET imaging in non-human primates
(NHPs) is presented here. The complete method from acquisition
of
18F, through automated synthesis, purification and formulation
for intravenous injection can be performed in less than 100
minutes. The method enabled the first syntheses of [
18F]-1 and
[
18F]-2, provided material sufficient in quality and quantity for
PET brain imaging studies in NHPs, and showcased the ability to
obtain
18F-labeled molecules in high specific activity for PET
imaging in NHP that would be challenging to obtain with
conventional fluorination methods. Our results establish that the
palladium-mediated fluorination has the potential to serve as a
research tool for in vivo imaging in drug discovery and radiotracer
development.
Results and Discussion
Development of an Electrophilic Fluorination Reagent
Derived from Fluoride
Radiofluorination with electrophilic
18F is challenging because
the reagent most often used, [
18F]fluorine gas ([
18F]F2), is difficult
to work with, requires specialized equipment, and is made in low
specific activity [3]. To efficiently liberate
18F from the target, the
sample is purposefully diluted with [
19F]F2. While progress has
been made to improve the isotopic enrichment of [
18F]F2 [11], the
specific activity of molecules synthesized from [
18F]F2 cannot
reach the level of [
18F]fluoride because only one of the fluorine
atoms of [
18F]F2 is
18F. Furthermore, radiochemical yield can be
at most 50% because only one of the fluorine atoms is transferred,
with essentially equal probability. Methods have been devised to
synthesize more practical electrophilic radiofluorination reagents
[25,26,27], but they have all been derived ultimately from [
18F]F2.
Nucleophilic [
18F]fluoride is a more practical source of
18F,
because it is widely available and produced without purposeful
dilution with
19F. However, nucleophilic fluorination reactions are
challenging to transition to radiochemistry given hydrated
fluoride’s limited nucleophilicity. A practical electrophilic radio-
fluorination reaction using high specific activity [
18F]fluoride may
enable new areas of PET imaging research.
We reported the first high-valent transition metal fluoride
complexes observed to undergo reductive elimination to form aryl
fluorides [28,29]. We subsequently discovered that high-valent
palladium fluoride complexes could behave as electrophilic
fluorination reagents, when other reductive processes such as
reductive elimination were inhibited by an appropriate choice of
ligands [24]. But, high-valent transition metal fluorides, including
those described in our original report [28], are typically themselves
synthesized from electrophilic fluorination reagents and not from
fluoride, which would not overcome the specific activity challenge
when dealing with
18F. Therefore, we designed a high-valent
organometallic complex 6 that can capture fluoride via ligand
exchange to form a high-valent transition metal fluoride complex
7, which can serve as an electrophilic fluorination reagent
(Figure 2). The complex was synthesized via benzo[h]quinoline
cyclopalladation, followed by ligand exchange with potassium
tetrapyrazolyl borate to afford palladium(II) complex 3 that was
oxidized to high-valent palladium(IV) complex 5 using the l3-
iodinane reagent 4. Exchange of the apical 4-cyanopyridine ligand
Figure 1. Two small molecule aryl fluorides chosen for radio-
fluorination and non-human primate PET imaging presented
here.
doi:10.1371/journal.pone.0059187.g001
18F-Fluorination with Palladium for PET Tracers
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Complex 6, which can be synthesized on multi-gram scale, is not
unique in its ability to capture fluoride. For example the pyridine
(instead of picoline) analog of 6 can capture fluoride as well (see
Supporting Information S1). Nevertheless, 6 is currently the
complex of choice because the picoline ligand imparts enough
electron-donating character to the electron-deficient palladium
center for long-term storage, but can quickly be displaced by
fluoride.
Important Characteristics of High-valent Organometallic
Complexes 6 and 7
Complex 6 can capture
18F from samples of [
18F]fluoride
(Figure 3, Step 1) and then serve as an electrophilic
18F
fluorination reagent (Figure 3, Step 2). Complex[
18F]-7 can be
used as the electrophilic reagent, for the fluorination of
pyridylsulfonamide-stabilized palladium (II) complexes 9 (see
Figure 4) [30], and can provide access to electron-rich, electron-
neutral, and electron-poor functionalized aryl fluorides. High-
valent palladium complex 7 is likely the first of a class of complexes
that exhibit the desired reactivity (capture and electrophilic
transfer of fluoride to make C–F bonds).
The ability of 6 and 7 to capture and transfer fluoride is
unusual. Complex 7 functions as an electrophilic reagent, similar
to conventional electrophilic fluorination reagents previously used
[30]. Yet, unequivocally, fluoride is the original source of fluorine.
The generation of an electrophilic fluorination reagent from
fluoride, without electrochemical methods, is challenging because
fluorine is the strongest elemental oxidant known. From an
electrostatic standpoint, the electropositive palladium center of
complex 6 is able to attract the fluoride anion. High-valent
palladium(IV) fluoride 7 was designed to prevent unproductive C–
F reductive elimination by the inclusion of multidentate ligands.
Reductive elimination from octahedral complexes is typically
preceded by ligand dissociation to a penta-coordinate species
[29,31], which is disfavored by multidentate ligands. Additionally,
tetrapyrazole borate ligands possess the ability to coordinate in
either a bidentate or tridentate mode and can switch between
them to accommodate the appropriate coordination chemistry
needed. Specifically, tridentate coordination is important to
stabilize the octahedral geometry for Pd(IV)d
6, but, with minimal
structural reorganization, bidentate coordination, of a square
planar Pd(II)d
8 complex is possible, the geometry of the complex
resulting after fluoride transfer. The ability to access different
coordination modes may lower the activation barrier to fluorina-
tion. Finally the triflate counterion was chosen because it is non-
coordinating so as to not displace fluoride from the palladium
center, and it does not contain readily exchangeable fluoride.




19F into the sample and lower the
specific activity of the final molecule.
Synthesis and Radiofluorination of Complex Small
Molecules
Radiolabeled [
18F]-7 can be used as the electrophilic reagent in
the palladium-mediated fluorination reaction we have previously
disclosed [30] to form radiolabeled aryl fluorides (Figure 4). The
mechanism of fluorination is proposed to occur by oxidation of
and transfer of fluorine from [
18F]-7 to 9 to form a new
Pd(IV)–
18F complex, which can then undergo C–F reductive
elimination to afford
18F-labeled aryl fluoride. Evidence for
oxidative fluorine transfer has been established: A high-valent
aryl Pd(IV)–F complex could be observed by NMR spectroscopy
after oxidation of an aryl Pd(II) complex, specifically 9 with the
aryl and pyridine substituent linked, with 7 [24]. Complex small
molecule substrates can be made in a modular fashion by
transmetalation of aryl boronic acid derivatives with palladium
acetate complex 8, synthesized in four steps from commercially
available reagents (see Supporting Information S1). Many
palladium(II) aryl complexes, for example 15 and 20 (substrates
leading to 1 and 2), can be purified by chromatography on silica
gel, are stable to air and moisture, and can be stored for extended
periods of time without decomposition (.1 year). Syntheses of
palladium aryl complexes 15 and 20 are shown in Figures 5 and 6.
Palladium complexes 15 and 20 were constructed from
commercially available starting materials using a placeholder
functional group at the eventual site of fluorination. For syntheses
via late-stage fluorination of 1 and 2, aryl bromides are used as the
placeholders then changed to aryl boronic esters that can undergo
transmetalation on to the palladium center in the penultimate step.
There are no radiochemistry time constraints associated with the
synthesis of the palladium aryl complexes, because
18F is only
incorporated after the palladium substrates are synthesized. For
the non-chemists, fluorination precursors (e.g. 15) are not trivial to
make, but could be made available for purchase. Palladium
complex 15, the precursor to paroxetine (1) is synthesized via a
route similar to a published route [32], but with an aryl bromide in
lieu of an aryl fluoride, which simplifies access to the desired
substrate. Alkylation, acylation, and cyclization reactions starting
form of 1-(4-bromophenyl)-3-chloropropan-1-one affords dihydro-
pyridone 10 (Figure 5). Asymmetric conjugate reduction using
conditions developed by Buchwald [32] provide enantioenriched
d-lactam 11 in 88% ee. Recrystallization of an intermediate later in
the synthesis (12) provides material that is .99% ee. A Claisen
Figure 2. New electrophilic fluorination reagent. Synthesis of
high-valent palladium complex 7 that is an electrophilic fluorination
reagent derived from complex 6 through fluoride capture.
doi:10.1371/journal.pone.0059187.g002
18F-Fluorination with Palladium for PET Tracers
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group exchange followed by Mitsunobu reaction with sesamol and
DIAD affords 13 that possesses the full carbon skeleton of
paroxetine. Borylation yields 14 and transmetalation provides
palladium complex 15.
For the palladium complex 20 leading to 5-HT2C agonist 2,
alkylation, olefination, and reduction of 5-bromosalicaldehyde
affords allylic alcohol 16 that is used in a Charette asymmetric
cyclopropanation reaction [33] to yield cyclopropane 17 in 96% ee
(Figure 6). The enantiomeric excess can be upgraded at a later
point (18) via recrystallization to .99% ee. Alcohol to amine
conversion and deprotection leads to the aryl bromide 18 that
undergoes palladium-catalyzed borylation to afford 19. Aryl
boronic ester is converted to palladium complex 20 through
transmetalation.
We have found that the yield of the ‘‘cold’’ (
19F) fluorination
reactions for a given substrate roughly correlates with the
radiochemical yield of the ‘‘hot’’ (
18F) fluorination reactions.
Palladium aryl substrates 15 and 20 were fluorinated with the
non-radiolabeled (
19F) version of palladium complex 6 to afford
small molecule aryl fluorides 21 and 22 in 71% and 72% yield,
respectively (Figure 7; Equations 1 and 2). Removal of protecting
groups reveals paroxetine (1) and the 5-HT2C agonist 2.
Scope and Limitations of Fluorination Reaction
Fluorination of 15 and 20 demonstrates the functional group
toleranceofourprotocol,andestablishesthatlate-stagefluorination
inthepresenceofavarietyoffunctionalgroupispossibleforelectron-
rich arenes, that are often challenging to prepare with conventional
fluorination reactions. Currently, our method does not tolerate
nucleophilic, basic functional groups, such as certain amines. While
pyridine-substituentsaretolerated,aminesofhigherbasicitysuchas
tertiary alkyl amines are not. We have overcome this limitation in
some cases through the use of protecting groups such as the Boc
groups used for substrates 15 and 20. Additionally, substitution
besides hydrogen ortho to the site of fluorination reduces the
efficiency of palladium aryl substrate synthesis and fluorination. An
additional limitation is the required synthesis of the palladium
complexesthemselves. Whilegenerallystable,thesynthesisrequires
some knowledge oforganometallic chemistry.
Figure 3. Two-step procedure for synthesis of radiolabeled aryl fluorides. The procedure consists of capture of [
18F]fluoride by
palladium(IV) complex 6 to form electrophilic
18F-fluorination reagent [
18F]-7 and fluorine transfer to aryl metal complexes.
doi:10.1371/journal.pone.0059187.g003
Figure 4. General palladium-mediated synthesis of radiolabeled aryl fluorides. C–F bond formation is proposed to occur by oxidation of 9
with [
18F]-7 leading to a proposed Pd(IV)–
18F intermediate followed by C–F reductive elimination.
doi:10.1371/journal.pone.0059187.g004
18F-Fluorination with Palladium for PET Tracers
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18F]fluoride was prepared following common
radiochemistry protocols from a sample produced in [
18O]H2Ob y
a cyclotron [34]. Second, we adapted the procedures for the
difference in stoichiometry between reactions with
19F and
18F.
For high specific activity [
18F]fluoride reactions only nanomoles of
the electrophilic fluorination reagent are synthesized, which
remain in the presence of a large excess of 6, the palladium
precursor. In practice, we found that it was not feasible or
advantageous to rapidly and cleanly isolate [
18F]-7 from the
mixture. Therefore, the
18F method was modified into a two-step
process with the reagent [
18F]-7 made in situ.
The two-step fluorination reaction can afford radiolabeled aryl
fluorides on a scale suitable for PET imaging (Figure 8). Several
variables were explored and optimized to accomplish efficient and
quick fluorination with [
18F]-7. Samples of [
18F]fluoride in H2O
with KHCO3 and the common phase transfer reagent, 18-crown-
6, were azeotropically dried with MeCN and acetone (Figure 8A).
18-Crown-6 was chosen instead of common cryptand phase
transfer reagents (e.g. KryptofixH 2.2.2), because 5 reacts
unproductively with the amine functionality found in KryptofixH
2.2.2. Initial variability in terms of overall radiochemical yield was
often associated with the drying process (‘‘dry-down’’) and re-
solubilizing of fluoride. While the reaction tolerates the presence of
water, the efficiency decreases as water concentration increases.
Next, palladium complex 5, dissolved in acetone, was added for
fluoride capture to form fluorinating reagent [
18F]-7 in less than
10 minutes. Before fluorination, the reaction mixture is filtered
over a pyridine-functionalized resin, JandaJel
TM, as a quick
intermediate purification step, which resulted in higher yields
compared to experiments omitting filtration. Filtration removes
byproducts that precipitate during the reaction. Pyridine-functio-
nalized solid support is more effective than other filtration
methods, which may be due to pyridine capturing 5 by displacing
Figure 5. Synthesis of palladium(II) aryl substrate 15.
doi:10.1371/journal.pone.0059187.g005
Figure 6. Synthesis of palladium(II) aryl substrate 20.
doi:10.1371/journal.pone.0059187.g006
18F-Fluorination with Palladium for PET Tracers
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added, and the resulting solution was heated at 85uC in a sealed
vial.
Generally, radiochemistry methods are first explored using
hand manipulations on a small amount of radioactivity (,500 mCi
of [
18F]fluoride). However, a typical PET imaging experiment in
NHPs requires 5–10 mCi of final radiolabeled pure product,
which along with the efficiency of the reaction dictates that the
starting amount of [
18F]fluoride needs to be anywhere from
50 mCi to 1 Ci of radioactivity. Currently, our fluorination
method requires starting with 1 Ci to produce enough for NHP
PET imaging experiments. Due to safety considerations, automat-
ed synthesis protocols were developed using a commercially-
available platform and took place inside of a hot cell. Synthesis
modules were programmed to run the reaction (azeotropic drying,
fluoride capture, filtration, and fluorination; see Supporting
Information S1). The automated procedures can now be used to
produce tens of mCi of radiolabeled aryl fluorides prior to
purification (Figure 8B and 3C).
Post synthesis protocols include 1) filtration through a plug of
silica to remove bulk metal contaminants, 2) removal of protecting
groups, 3) HPLC purification for isolation, and 4) formulation in a
sterile solution for administration. Post synthesis manipulations are
currently conducted by hand, though ideally will be automated in
the future.
While protecting groups are common in radiochemistry,
deprotection reactions must be fast and efficient. For the two
radiolabeled molecules in this research, we chose to protect the
primary and secondary amines with easily removable t-
butoxycarbonyl (Boc) groups. Exposure of [
18F]-21 and
[
18F]-22 to trifluoroacetic acid for two minutes revealed the
ammonium salts.
Because the mass of fluorinated material using high specific
activity [
18F]fluoride is typically less than 10 mg among milligrams
of reaction reagents, HPLC can be an efficient and often used [35]
tool to remove contaminants and byproducts. We have devised
routine HPLC methods that purify [
18F]-1 and [
18F]-2 with
standard semi-preparatory columns in less than 15 minutes. Final
samples are chemically and radiochemically pure and have less
than 5 parts per billion palladium (ppb) content, well below
suggested guidelines for use in humans (,1000 ppb) [36]. The
residual amount of palladium was determined by inductively
coupled plasma mass spectroscopy (ICP-MS) analysis.
After HPLC purification, the sample is captured with a solid
phase extraction column and formulated in a sterile saline
solution. Final samples were analyzed for purity, residual solvent,
pH, pyrogenicity, and sterility and passed all quality control
protocols generally used for PET imaging in NHPs.
Starting with an approximated 1 Ci of radioactivity, our
method can be used to produce .10 mCi of formulated product
in up to 13 Ci/mmol specific activity at time of injection (TOI),
suitable for imaging primates. The entire process from obtaining aqueous
samples of
18F through formulation can be accomplished in less than 100 min.
Non-human Primate PET Imaging with [
18F]-1 and [
18F]-2
Using the procedure outlined above, we prepared [
18F]-1 and
[
18F]-2 for use in four separate MR-PET imaging experiments in
baboons (Papio anubis). The objective of these studies was to
determine the brain pharmacokinetic profile and distribution of
[
18F]-1and [
18F]-2 and compare the binding and kinetic profile
to scans performed after a drug challenge. This ‘‘test-block’’
procedure provides information about the nature of the radioac-
tive signal that is observed. The initial protocol is designed to
determine the contribution of specific and non-specific binding to
the PET signal. Specific binding interactions, (i.e. [
18F]-1 with
SERT [37]; [
18F]-2 with 5-HT2C), will undergo competition with
drug pretreatment resulting in an overall reduced PET signal;
however binding interactions that are non-specific and not in
competition with the drug will remain the same. Determining the
Figure 7. Synthesis of aryl fluorides 1 and 2 via late-stage fluorination with electrophilic reagent 7.
doi:10.1371/journal.pone.0059187.g007
18F-Fluorination with Palladium for PET Tracers
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is the first and most crucial step in radiotracer validation for
receptor systems in the brain; it is also one of the least predictable
outcomes in radiotracer development [38]. We chose blocking
drugs (citalopram [39] 5.0 mg/kg for SERT; ritanserin [40]
0.1 mg/kg for 5-HT2C) that were known to be safe for
administration intravenously [41,42] rather than performing self-




Radiolabeling drug molecules with positron-emitting isotopes
has intrinsic value, which is particularly true of central nervous
system (CNS) drugs. Inferences about brain penetration and
pharmacokinetic profile (PK) in humans are often made through
extrapolation from studies in lower mammals and drug
concentrations in human plasma, because observing drug
concentration at target sites in vivo in humans is challenging.
Many drug molecules, commonly prescribed for the human
CNS, are used without any knowledge of human brain PK.
Understanding the brain distribution and kinetic profile of drugs
or drug candidates in humans can help understanding drug
failures and may ultimately provide better predictive tools for
success in drug development [43,44]. While there are many
reasons why drugs are not often labeled and evaluated with
PET, a striking number of molecules cannot be labeled with
either of the two most common PET isotopes, carbon-11 and
fluorine-18. Paroxetine, a selective serotonin reuptake inhibitor,
is a good example of a molecule that was previously considered
inaccessible for high specific activity labeling approaches. The
challenge of labeling paroxetine (1) was overcome using
palladium-mediated fluorination and provided [
18F]-1 in
suitable yield for initial studies in NHPs.
Figure 8. Palladium-mediated synthesis of [
18F]-1 and [
18F]-2 using [
18F]-7 derived from [
18F]fluoride. (A) Synthesis of the electrophilic
fluorination reagent [
18F]-7 for reaction with palladium aryl complexes. (B) Synthesis of SSRI [
18F]-1 on a scale suitable for NHP PET imaging. (C)
Synthesis of 5-HT2C agonist [
18F]-2 on a scale suitable for NHP PET imaging.
doi:10.1371/journal.pone.0059187.g008
18F-Fluorination with Palladium for PET Tracers
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Pharmacokinetic Profile
Two MR-PET imaging studies were performed with [
18F]-1,a
baseline and a challenge with citalopram, a competitive serotonin
reuptake inhibitor. The baseline scan revealed modest brain
penetration (0.013% ID/cc) corresponding to about 1.7% of the
total injected dose accumulating in the brain. Penetration into and
accumulation in the brain were rapid (Figure 9), reaching a
plateau between 15–30 min. Washout kinetics were markedly slow
with a t1/2 calculated from the data (35–90 min) of 21. 3 h. This is
consistent with the plasma half-life range (21–24 h) reported in the
monograph for Paxil [45] (one of the trade-names for paroxetine).
The accumulation of [
18F]-1 represents predominantly non-
specific uptake in the brain. Heterogeneous binding was observed,
but was inconsistent with the known SERT distribution from PET
studies with validated radiotracers such as [
11C]DASB [23]. The
lack of specific binding was confirmed by citalopram challenge, in
which there was no significant change in the accumulation and
distribution of [
18F]-1 relative to baseline. Although data analysis
with [
18F]-1 may be limited by the high degree of non-specific
binding, the prevalence of paroxetine used to treat depression
warrants evaluation of brain PK and distribution in humans.
PET Study to Evaluate a Potential PET Radiotracer
Our choice to evaluate [
18F]-2 as a selective radiotracer for the
serotonin 2c (5-HT2C) receptor was based upon the growing
associations between 5-HT2C and brain-related disorders
[46,47,48,49]. Although the associations exist, the 5-HT2C
receptor has previously received less attention in psychopharma-
cology and neuroimaging than its homolog, 5-HT2A. To date,
selective 5-HT2C radioligands for autoradiography and 5-HT2C
radiotracers for imaging have not been described, a fact which has
no doubt hindered research in neurobiology. Due to the recent
development of novel scaffolds for potent and selective ligands of
5-HT2C, in vivo imaging of 5-HT2C has become a realistic goal
[46]. Very few, if any, of the molecules that selectively target 5-
HT2C are obvious labeling candidates for either carbon-11 or
fluorine-18; much less, compounds for which in vivo data support
the likelihood for radiotracer development success. Agonist 2 was
chosen from the literature not only because it was well-suited for
the chemistry described, but also because of its selectivity profile
(40-fold and 14-fold selective for 5-HT2C over 5-HT2A and 5-
HT2B, respectively) and its demonstrated efficacy in an animal
model of antipsychotic drug activity [21]. To our knowledge, this
is the first reported evaluation of a 5-HT2C-targeted molecule for
use in PET.
Two preliminary imaging studies in non-human primates were
used to determine whether [
18F]-2 exhibited suitable blood-brain
penetration, pharmacokinetic profile, and specific binding suitable
for use as a 5-HT2C PET tracer (Figure 10). Data from the
baseline study indicate that [
18F]-2 has excellent brain penetra-
tion with an average brain : plasma ratio of 1.5 at 30 minutes post
injection. Analysis of arterial plasma from this experiment
suggested that the compound had suitable metabolic stability
(nearly 70% of radioactivity in plasma was associated with intact
[
18F]-2 at 60 min) to warrant continuation to pharmacological
challenge studies. For the initial drug challenge, we chose
ritanserin, which is a non-selective 5-HT2A (EC50=4.6 nM), 5-
HT2B (2.2 nM), and 5-HT2c (6.6 nM) antagonist [50]. We
observed a modest 15% decrease in uptake of [
18F]-2 following
ritanserin administration. The decrease was observed in the
thalamus and throughout the cortex (frontal, medial parietal and
temporal), but not in the cerebellum. Decreases in the thalamus
and cortex are reasonably correlated with expectations from 5-
HT2C mRNA mapping in the monkey [51] and human brains
[52] ex vivo. The lack of blockade in the cerebellum is also
consistent with the assumed 5HT2c receptor distribution. One
notable exception is that higher levels of uptake and blockade were
anticipated in the choroid plexus. Our preliminary data, which
indicate modest specific binding, are encouraging and warrant
additional studies to more accurately quantify the reduction in
binding potential of [
18F]-2 during pharmacological challenge.
Methods
See Supporting Information S1.
Conclusions
We have developed a modern fluorination reaction with large
substrate scope that can be used for the synthesis of complex
18F-
labeled aryl fluorides suitable for imaging in NHPs. Our synthesis
of radiolabeled aryl fluorides employs [
18F]fluoride, is fast, high-
yielding, and affords only one aryl fluoride constitutional isomers
and no inseparable byproducts. We have demonstrated that our
method can be translated to synthesize radiolabeled aryl fluorides
[
18F]-1 and [
18F]-2 in quantity and quality suitable for PET
imaging studies in baboons to obtain pharmacokinetic data. Our
method can tolerate a large variety of functional groups, and is
suitable for electron-rich and –deficient arenes, which is a
Figure 9. Distribution and pharmacokinetic profile of [
18F]paroxetine ([
18F]-1) from MR-PET imaging in non-human primates. (A)
Summed images from 5–50 min of the dynamic PET collected following injection of [
18F]-1. The images are fused with a structural (T1 weighted) MR
image. Although [
18F]-1 is a potent and selective ligand for the serotonin transporter (SERT), the observed binding does not match the distribution
of SERT. This is indicative of high non-specific binding. The images highlight the overall high blood-brain-barrier penetration of [
18F]-1 and
heterogeneity of binding observed. (B) Whole-brain average time-activity curves from [
18F]-1 from baseline and pretreatment (citalopram) studies.
doi:10.1371/journal.pone.0059187.g009
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tions of the method are the inability to tolerate certain nucleophilic
functional groups, most notably tertiary amines, and the substan-
tially lower yields for substrates with ortho substitution. Moreover,
our method is not as simple to perform as a conventional
nucleophilic aromatic substitution reaction and requires the
synthesis of organotransition metal reagents.
We see utility in our method for the predictable synthesis of
18F-
labeled molecules that can support drug development, for
example, small molecule drug candidates with drug-like structures
such as paroxetine can now be labeled. In addition, we provide a
tool that enables the synthesis of
18F-labeled molecules for
evaluation as potential PET tracers that report on a biological
function. PET tracer development is challenging beyond synthesis,
as exemplified by the high-nonspecific binding of paroxetine,
which makes [
18F]paroxetine ([
18F]-1) unsuitable for imaging of
SERT. But the ability to make more complex and structurally
more diverse
18F-labeled molecules more quickly, more reliably,
and more efficiently than previously possible, may shift the future
challenge toward PET tracer development rather than PET tracer
synthesis. New fluorination methods that expand the number and
types of molecules that can be radiolabeled blended with advances
in tracer development should increase the impact of PET imaging.
In this respect, we are particularly excited about a new method
developed in our group, which is based on nickel complexes [53],
and may be more easily executed, also by the non-expert.
Supporting Information
Supporting Information S1 Contains details on materi-
als and methods, experimental data for chemistry and
radiochemistry, and spectroscopic data.
(PDF)
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